BXT-51072 and other Glutathione Peroxidase (GPx) Mimic Compounds
OXIS' mimics of the naturally occurring antioxidant enzyme, glutathione peroxidase or GPx, are small molecular-weight chemical catalysts that can be taken orally as well as intravenously. The company's lead compound is BXT-51072.
BXT-51072 is a low molecular weight, orally active, organoselenium catalytic mimic of the major cellular protective antioxidant enzyme, glutathione peroxidase (GPx). In addition to its direct peroxide neutralizing capabilities, BXT-51072 regulates secondary inflammatory processes by preventing the activation of inflammatory mediators such as cytokines, adhesion molecules and inflammatory enzymes, apparently by inhibiting the nucleic transcription mechanisms that govern their production. BXT-51072 is initially being developed for use in the treatment of inflammatory bowel diseases, and has already demonstrated efficacy in a preliminary Phase 2 study ulcerative colitis and is currently being tested in other applications.
Oxis has recently entered into a worldwide exclusive license with Alteon, Inc. for BXT-51072 and the other Oxis Glutathione mimic compounds for all applications of the compounds. Alteon's lead compound under this license, is currently in a Phase 2 clinical study for cardiovascular indications. By mimicking glutathione peroxidase (GPx), ALT-2074 may protect against excessive oxidation of lipids and thereby limit inflammation. Alteon believes that the compound may be useful in patients with diabetes, whose cardiovascular disease may be caused by high levels of circulating oxidized lipids and associated inflammation. Further information on the Alteon licensing deal can be found here.